First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

Por Helmer, Eric, Watling, Mark, Jones, Emma, Tytgat, Dominique, Jones, Mark, Allen, Rodger, Payne, Andrew, Koch, Annelize, Healy, Eugene
Publicado no Eur J Clin Pharmacol (2017)

SMALL MOLECULE RECEPTOR AGONISTS AND ANTAGONISTS OF CCR3 PROVIDE INSIGHT INTO MECHANISMS OF CHEMOKINE RECEPTOR ACTIVATION

Por Wise, Emma L., Duchesnes, Cécile, da Fonseca, Paula C.A., Allen, Rodger A., Williams, Timothy J., Pease, James E.
Publicado em 2007

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037

Por Haagensen, Emma J., Thomas, Huw D., Schmalix, Wolfgang A., Payne, Andrew C., Kevorkian, Lara, Allen, Rodger A., Bevan, Paul, Maxwell, Ross J., Newell, David R.
Publicado no Cancer Chemother Pharmacol (2016)

mTOR direct interactions with Rheb-GTPase and raptor: sub-cellular localization using fluorescence lifetime imaging

Por Yadav Rahul B, Burgos Pierre, Parker Anthony W, Iadevaia Valentina, Proud Christopher G, Allen Rodger A, O'Connell James P, Jeshtadi Ananya, Stubbs Christopher D, Botchway Stanley W
Publicado em 2013-01-01

mTOR direct interactions with Rheb-GTPase and raptor: sub-cellular localization using fluorescence lifetime imaging

Por Yadav, Rahul B, Burgos, Pierre, Parker, Anthony W, Iadevaia, Valentina, Proud, Christopher G, Allen, Rodger A, O'Connell, James P, Jeshtadi, Ananya, Stubbs, Christopher D, Botchway, Stanley W
Publicado em 2013